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Clinical reactions and serologic in all cases, to alpha globulins in 9 cases, and to 
SuMM*~y changes after intramuscular ad- gamma globulins in only 1. This h d i n g  indicates 
ministration of horse anti-human lymphocyte that a safer ALG could be made by removing the 
globulin (ALG) were studied in 53 human re- trace quantities of alpha and beta globulins from 
cipients of renal homografts. The ALG was used the immunologically more active gamma globu- 
as an adjuvant immunosuppressive drug. In the lins. 
usual case 47 injections were given over a 4-month 
period. 
All patients had pain, tenderness, erythema, D URING THE LAST 14 MONTHS more than and swelling at the injection sites. Benign systemic 2,000 intramuscular injections of 
side effects included fever in all cases, hives in horse anti-human lymphocyte globulin 
eight cases, rash in five, pruritus in five, arthralgia 
in three, and periorbital edema in one. Anaphy- (ALG) have been given to 53 Of 
lactic reactions occurred in 11 cases. These were renal homografts. The potent immuno- 
easily treated, and there was complete recovery suppressive properties of antilymphocyte 
in every instance within 90 min. In  eight of these 
cases the ALG administration was discontinued. Serum (ALS) Or its globulin derivative 
Subsequent injections were given in the other have been known since the report of Waks- 
three. 
Four of 11 patients tested had positive skin 
tests to ALG before therapy. Antibodies against 
sheep red blood cells developed during therapy in 
39 of 40 patients; 10 reached titers as high as 
1:128 to 1:512. Precipitin antibodies as mea- 
sured with an electroirnmunodifTusion technique 
developed in 36 of 40 patients. All three immuno- 
logic tests were of value in predicting the proba- 
bility of an anaphylactic reaction, but the dis- 
crimination was imperfect. 
Immunoelectrophoretic studies of sera from 13 
patients showed antibodies to horse beta globulins 
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man, Arbouys, and Arnason (1). The abil- 
ity of these agents to mitigate or even pre- 
vent rejection of skin homografts in inbred 
mice was first unequivocally demonstrated 
by Woodruff and Anderson (2). Since then, 
many investigators have noted these prop- 
erties of both ALS and ALG, as has been 
recently summarized in accounts of our 
.own canine studies with whole-organ kid- 
ney and liver transplantation (3, 4). 
In most of the aforementioned studies 
the heterologous serum and globulin were 
evaluated as the sole therapy. I t  has also 
been shown that ALG has a synergistic ac- 
tion with other immunosuppressive agents 
t(3, 5, 6), and in the clinical trial to be de- 
scribed the immune globulin was used in 
combination with azathioprine and predni- 
sone. Smaller doses of the latter drugs were 
sufficient to achieve adequate homograft 
protection (3, 4). The incidence of septic 
complications was reduced, and the 1-year 
survival of recipients of consanguineous 
homografts was increased to 95% (7). 
These benefits have not been without 
corresponding penalties, as will be docu- 
mented by an analysis of the clinical tox- 
icity and the serologic changes in the first 
53 patients who received treatment with 
ALG. In reviewing the findings attention 
will also be directed to possible ways in 
which ALG might be improved for future 
use. 
METHODS 
CASE MATERIAL 
Between June 1966 and August 1967 all pa- 
tients who received renal homotransplantation 
at our institutions were treated with horse 
ALG. which was used as an adiuvant to ther- 
twice a week for 2 months, and once a week 
for a final month. A full course consisted of 
approximately 47 injections, but 2 patients 
received 79 injections each. 
There were an additional five patients who 
received a similar course of ALG therapy from 
39 to 11 months after transplantation in an 
effort to reduce the doses of prednisone and 
azathioprine that were required to prevent an 
insidious progressive rejection. Two of these 
five patients are still alive. 
The features of the ALG used in this study 
have been described elsewhere (8). I t  was pre- 
pared by ammonium sulfate precipitation of 
the serum of horses that had been immunized 
against human spleen, lymph node, and thymus 
lymphocytes. Approximately 90% of the pro- 
tein was gamma G globulin. The rest was 
T-equine, beta, and alpha globulin. The total 
protein content varied from 4.6 to 10.8 g/100 
ml, and the leukoagglutinating titer varied be- 
tween 1:4,000 and 1:32,000. The individual 
doses were 1 to 5 ml. During the period of 
daily injections the protein doses per week 
were 10 to 50 mg/kg body weight. 
The way in which azathioprine and predni- 
sone were used did not differ from that in 
previous cases (9), except that smaller doses of 
both were required to prevent rejection, as 
documented elsewhere (3 ,  4, 7). In a few cases 
prednisone was given in the absence of rejec- 
tion, usually because of rising titers of precipi- 
tins or hemagglutinins or both. 
The courses of four patients in the group 
were of unusual interest since they received two 
series of h rote in iniections. The initial in- 
jection schedules were for 5 days, 1 week, 1 
month, and 4 months, respectively. The subse- 
quent intervals were for 2, 3 ,  2, and I t  months. 
The second courses were for a full 4 months 
in all but the first patient, who died 7 days after 
globulin reinstitution. The death, which oc- 
curred 2 days after transplantation, was due to 
a surgical complication. 
apy with azathioprine and prednisone. In 42 
cases the homografts were obtained from fa- 
milial donors; 37 of these recipients are still 
alive, with good renal function. Of six similar 
patients who received cadaveric homografts, 
four survive to date. 
The ALG was ordinarily given daily for 5 
days before operation, except in the cadaveric 
cases where pretreatment was omitted. After 
transplantation injections were given each day 
for 2 weeks, then every other day for 2 weeks, 
S ANTILYMPHOCYTE GLOBULIN 
(IS). Slides were coated with 1% agar in veronaI 
buffer (pH, 8.6; ionic strength, 0.05). Wells 
and troughs were cut. Normal horse serum was 
placed in the wells and electrophoresed at  7 
v/cm for 45 min in veronal buffer (pH, 8.6; 
mined by a micro technique (10) in which ionic strength, 0.1). The serum to be analyzed 
patients' sera were tested against a 2% ssupen- was placed in the trough and incubated for 
sion of sheep red blood cells to determine the 24 to 72 hr. The slide was fixed and stained 
presence of Forssman-like antibodies (11). with amido black, and the nature of the anti- 
Precipitin Titers: These were determined by body was identified by the localization of the 
the electroimmunodiffusion method of Merrill, precipitin band. T o  aid in the accurate de- 
Hartley, and Claman (12). Glass slides were lineation of the immunoglobulin classes, similar 
coated with 1% Difco purified agar in veronal experiments were done using specific rabbit 
buffer (pH, 8.6; ionic strength, 0.05) to which anti-horse serum + instead of human serum. 
5 m1/ 100 ml of normal horse serum were added. 
Seven wells, each 2 mm in diameter, were cut RESULTS 
in the slide to accommodate the samples being 
analyzed. Electrophoresis was carried out for 
60 min at  7.5 v/cm in veronal buffer (pH, 8.6; 
ionic strength, 0.1). The slides were then fixed 
and stained with amido black. 
To  create an arbitrary numerical scale, 
pooled sera of two patients with known sensi- 
tivity to horse protein were prepared in serial 
twofold dilutions and subjected to electro- 
immunodiffusion. A semilogarithmic plot of 
the length of the precipitating bands of these 
serially diluted sera produced a straight line 
which was used as a standard against which the 
serum being tested could be compared. The 
length of the band at 1:l dilution of the pooled 
control sera was defined as 100 units. The 
method provided an extremely sensitive way of 
following serial changes in titer in the ALG- 
treated patients, but only as these related to 
the precipitin content in the standard sera. 
It was not feasible to obtain accurate nitro- 
gen weights of the precipitins in either the 
standard or the test sera, since the antibodies 
proved to be heterogenous. The precipitin titer 
of the undiluted standard serum,' as measured 
by the ring method of twofold dilution of anti- 
gen (normal horse serum), was 1:5,120. 
Further Characterization of Precipitin Re- 
sponse: These studies were done to determine 
if the human antibody response was directed 
against specific classes -of horse immunoglobu- 
lins. The pooled serum from two patients 
known to have been sensitized to ALG was 
tested by placing it in wells cut from agar that 
contained 250 pg/ml of purified horse alpha, 
beta, or gamma globulins (Cohn's fractions IVI, 
111, and 11, respectively.+ 
Immunoelectrophoresis was performed on 
the serum of 12 other globulin-treated patients, 
using a modification of Scheidegger's method 
Hyland Laboratories. Los Angeles. Calif. 
CLINICAL OBSERVATIONS 
Local Eflects: Every patient had pain and 
tenderness at the site of injection, which 
was usually in the buttock. Although the 
discomfort varied from patient to patient, 
it was characteristically severe, especially 
with the first several and the last few in- 
jections. I t  would begin within 2 to 3 hr 
and reach a peak within several hours; it 
often lasted for 4 to 24 hr. In many cases 
the pain was not confined to the gluteal 
region but involved the whole leg. Propoxy- 
phene hydrochloride (Darvona) gave fair 
relief, though the local application of heat 
was more effective. A number of patients 
found that motion of the involved leg, 
either active or passive, gave relief. Only 
a few had pain severe enough to require 
narcotics. 
Injections almost invariably caused local 
erythema and swelling. These findings were 
most noticeable as pain reached a peak but 
tended to persist longer. Occasionally, ery- 
thema and swelling involved the whole 
buttock and upper thigh. One patient had 
sunburn-like erythema on his left buttock 
after each shot- which matured like sun- 
burn and desquamated. Local itching was 
never severe but was noted by one third of 
the patients. Skin necrosis was not seen. 
Two patients formed gluteal abscesses at 
or near sites of ALG injection. In one 
abscess, which contained Clostridium sapro- 
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genes, the infection was believed to have 
been secondary to prior therapy with intra- 
muscular antibiotics. In the other patient 
who was being treated with anticoagulants 
for thrombophlebitis there was hemorrhage 
in the needle tract. The resulting abscess 
was sterile. Both patients had uneventful 
healing after incision and drainage. A third 
patient developed pneumococcal cellulitis 
in the buttock and thigh which was easily 
controlled with penicillin therapy. 
Systemic Eflects: Virtually all the patients 
developed fever both during the preopera- 
tive period, when ALG was the only im- 
munosuppressive agent being given, and 
later, when prednisone and azathioprine 
were also being administered. In most cases 
this was low-grade, but in some it spiked 
to 39 or 40 C, with a regular time relation 
to each injection. Many of these patients 
had chills. The more severe fevers had 
accompanying tachycardia. The only treat- 
ment given was aspirin. 
Other benign reactions included hives 
(eight cases), rash (five cases), and general- 
ized pruritus (five cases). These were ef- 
fectively treated with antihistaminic agents. 
Three patients had arthralgia, and one ex- 
perienced periorbital edema. 
E&n patients had anaphylactic reac- 
tions; in eight of these the ALG was im- 
mediately discontinued. In the other three, 
therapy was continued for more than a 
month and then was stopped either because 
of additional similar reactions or because 
the course of injections had been com- 
pleted. 
The anaphylactic reactions were abso- 
lutely characteristic. Within 1 to 30 min 
after injection the patients developed pro- 
found anxiety, followed by nausea and, 
sometimes, by an urge to defecate. Most 
complained of diffuse low-back pain and 
dyspnea. 
The usual physical findings were hypo- 
tension and cyanosis of variable severity. 
The blood pressure falls were sometimes 
minor, but in others the recorded values 
were 40 to 60 mm Hg. At this time cyanosis 
with distention of the neck veins was al- 
ways observed. Usually, the extent of de- 
saturation seemed far greater than the dis- 
comfort exhibited by the patient; in one 
case an arterial oxygen saturation of 20% 
was recorded. In the usual case a tempera- 
ture spike occurred, occasionally accom- 
panied by chills. 
Treatment was immediately instituted 
with 50 mg intravenous prednisolone and 
nasal oxygen. Many patients also received 
100 mg diphenhydramine hydrochloride 
(BenadrylB) intravenously. A liter of lac- 
tated Ringer's solution was given. Epineph- 
rine was not required. All patients recov- 
ered in 5 to 90 min. In no instance were 
there any demonstrable aftereffects. 
A number of other side effects of ALG 
were looked for. Nine of the patients had 
thrombocytopenia (< 50,000) at some time 
in the postoperative course at a time when 
leukopenia was not present, but this could 
have been attributable to the azathioprine 
which was also being given. Nevertheless, 
a reduction in ALG in two patients with 
low platelet counts was followed by a 
prompt relative thrombocytosis. Some of 
the batches of ALG being used have been 
shown to have platelet-agglutinating prop- 
erties (4). 
There were no neurologic complications, 
peptic ulcers, myositis, abdominal pain, or 
pericardial and pleural effusions. The first 
eight consecutive patients had hornograft 
biopsies after approximately 4 months of 
ALG therapy. As described elsewhere (4), 
there was no evidence of serum sickness or 
Masugi nephritis in any of the specimens. 
None of the four patients who were re- 
challenged with ALG injections from 16 
to 3 months after an original course of 
therapy had serious systemic reactions. 
IMMUNOLOGIC STUDIES 
Skin Tests: Before the institution of 
ALG treatment 4 of 11 patients had 
positive tests at 30 min, with wheal and 
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Hemagglutinin titers against sheep red blood cells in 40 patients receiving anti-human 
lymphocyte globulin (ALG). 
erythema. Three of these ultimately de- 
veloped anaphylactic reactions after weeks 
or months of intramuscular therapy. In 
contrast, none of the other seven patients 
had this complication even though they 
also eventually developed positive skin tests 
(Table 1). 
The skin test readings at 24 hr roughly 
paralleled those at 30 min. In addition, 
petechiae, vesicles, and necrosis were seen 
who later had 
ultimately developed hives and arthralgia. 
There were several others with negative 
pretherapy skin tests who also ultimately 
manifested the latter side effects after their 
intradermal reactions had become positive. 
Hemagglutinin T i t e r s :  Antibodies 
against sheep red blood cells developed 
in 39 of 40 patients. The titers increased 
in rough parallel with those of the precipi- 
tins to be described below, but more slug- 
gishly. In ten cases the hemagglutinin titers 
rose to 1: 128 to 1:512. In  seven of the ten 
there eventually was an anaphylactic reac- 
tion but usually some time after the peak 
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titer level had been reached. Thus, the Precipitin Titers: Precipitin reactions 
appearance of high levels of hemagglutinins were negative with electroimmunodiffusion 
was a warning of a possible anaphylactic in each of 40 patients before ALG injec- 
reaction (Figure l), but it did not predict tions. During therapy all except 4 had a 
when this would occur. rise in titer. The development of a high 
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FIGURE 2. Precipitin titers in units (see text) in 40 patients receiving anti-human lymphocyte 
globulin (ALC). 
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titer correlated with development of ana- 
phylactic reactions (Figure 2), but there 
was overlap. Of 6 patients who developed 
precipitin bands greater than 48 units, 5 
had anaphylactic reactions. Among the 
other 34 whose titers were always less then 
48 units only 2 exhibited such reactions. 
These 2 patients had a maximum of 34.7 
and 32.7 units. There was no correlation 
of the precipitin levels with other side 
effects such as hives and arthralgia. 
The rapidity of elevations in precipitin 
titers also seemed to be a significant prog- 
nostic sign. The patients who eventually 
had anaphylactic reactions tended to have 
detectable increases in precipitins at an 
early time, often within a few days or 
weeks after beginning therapy (Figure 2). 
In contrast, those who did not have this 
complication had more sluggish titer rises. 
In the majority of cases the precipitin titers 
began to subsequently decline even though 
the protein injections were continued and 
despite the fact that immunosuppression 
with prednisone and azathioprine was often 
being lightened. 
The early use of prednisone blunted the 
precipitin response. Patients who received 
steroids from the time of operation onward 
generally had low and slowly rising titers 
(Figure 3), while those who had prednisone 
therapy delayed (Figure 4) or withheld al- 
together usually showed a rapid increase to 
high levels. 
Three of the four patients who received 
a second course of ALG had falling pre- 
cipitin titers when therapy was reinsti- 
tuted; in the fourth, precipitating anti- 
TIME IN WEEKS 
FIGURE 3. Immunologic data on a patient who received two courses of anti-human lymphocyte 
globulin (ALG) therapy. The first was given in an attempt to control chronic rejection 5 months 
after a cadaveric transplant, and the second was given before and after retransplantation with 
a kidney from a related donor. Note that the hemagglutinin and precipitin responses were not 
accelerated with the second course. Prednisone was started immediately after the retransplanta- 
tion. No anaphylactic reactions occurred. The Greek symbols indicate the globulin classes 
against which the precipitins were directed. 
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CONTROL 
TIME IN WEEKS 
FIGURE 4. Immunologic data on a patient treated with anti-human lymphocyte globulin 
(ALG) for 15 weeks posttransplantation. Prednisone was not started until the fifth postoperative 
week and then was started because of the high serologic titers rather than for rejection. The 
Greek symbols indicate the globulin classes against which the precipitins were directed. 
bodies were not detectable during either 
course. With retreatment the precipitin 
bands in the first three patients rose to a 
maximum of 11, 42, and 45 units, respec- 
tively, but not at a more rapid rate than 
originally. The results were not correlated 
with changes in hemagglutinin titers since 
only one patient (Figure 3) had any secon- 
dary rise in the latter values. 
Characterization of Precipitin Response: 
With electroimmunodiffusion the pooled 
serum from the two patients known to be 
sepsitized to horse ALG showed a promi- 
nent band against horse beta globulin and 
a weak band against alpha globulin. There 
was only a trace of antibody against gamma 
globulin (Figure 5). 
The studies with the alternative method 
of immunoelectrophoresis tended to sup- 
port these findings. All IS patients studied 
had demonstrable antibodies to horse beta 
globulins at some time in their course, and 
9 developed antibodies to alpha globulins. 
Anti-gamma antibodies were found in only 
one patient (Table 2). 
DISCUSSION 
Although there has been a large number 
of recent reports of the ability of ALS and 
ALG to prevent homograft rejection in 
animals (14), there have been no accounts 
of the toxicity from the administration of 
these substances to man except for our own 
preliminary report (4) and those of Monaco, 
Wood, van der Werf, and Russell (15, 16). 
An 'impressive clinical literature sum- 
marized by Kojis (17) and Arbesman (18) 
exists on the side effects of animal protein 
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injections given as part of the treatment 
o l  LeLanus, diphtheria, gas gangrene, pneu- 
mococcal pneumonitis, and other infec- 
tions. However, it was hoped (4, 5, 19, 20) 
that the ~vell-known dangers of foreign pro- 
tein therapy ~vuuld be less with ALS or 
ALG since their action might be expected 
to retard an antibody response by the 
trca~ed subject; this has been referred to 
as a "self-antidotal" effect. The  concomitant 
administration of other inlmunosuppres- 
sive agents such as azathioprine and pred- 
nisone could be expected to provide an 
additional margin of safety. 
AGAR CONTAINING 57. nrrnn CONTAINING 250  yg/ml 
HORSE SERUM OF HORSE (COHN'S F R . E  
These expectations seem to have been at AGAR CONTAINING 250 M ~ I ~ I  AGAR CONTAINING 250 M Q / ~ I  
least partially fulfilled by the OF HORSE/' (COHN'S FR III) OF 'OR'' (COHN'S FR 11) 
herein reported, in which more than 2,000 FIGURE 5 .  Results with electroimmunodiffusiori OL 
individual inrramuscular injections of pooled sera from two patients known to bc sensi- 
tized to anti-human lymphocyte globulin when 
ALG given. There has been an scra were tested against ~vhole normal horse serum 
ALG-rrlated mortality among the 53 con- and several of its immunog~obulin fractions. Well 
secuti\.e Ijatien,s receivei a cours  of 1 =patient scrum undiluted; well 2 = 1:2 dilution; 
well 3 = 1:4 dilution; well 4 = 1:8 dilution; well 5 
therapy that usually lasted for 4 months. = 1:16 dilution; well 6 =  dilution; ,= 
Furthermore, there was no evidence in the 1:64 dilution. 
homografts of the first 8 of these patients 
~vho  received renal biopsies at the end of 
4 months that they had developed either 
Masugi or serum sickness nephritis in their 
transplants (4). Nevertheless, a clear warn- 
ing that the latter complication may occa- 
sionally occur was given in the report by 
Monaco, Wood, van der Werf, and Russell 
(15). who observed serum sickness nephritis 
in a normal volunteer who was being ad- 
n~ i~~ i s t c red  abbit gamma G globulin. 
The  more common undesirable effects of 
ALG administration were by no  means in- 
consequential. These invariably included 
pain and swelling at the site of injection 
as well as elevations in temperature which 
were sometimes to high levels. Rashes, 
hives, itching, arthralgia, and periorbital 
edema were occasionally noted. Thus, at 
some time a significant number of patients 
developed one or more of the clinical mani- 
fcstations of serum sickness as defined by 
Kojis (17). A possibility exists that throm- 
bocytoper ; d may also have occasionally 
beer. clused by ALG. 
None of the foregoing complication 
were life-threatening, and they were no 
considered indications for discontinuance 
of therapy. In contrast, the anaphylactic 
reactions that were seen in 21% of the 
patients led to a decision for immediate 
cessation of therapy in 8 of 11 cases despite 
the fact that more injections were given in 
the other 3 without serious consequences. 
The  anaphylactic reactions were variable 
in severity, but in every instance they were 
rather easily treated and of short duration. 
With increased experience it became easier 
to view such reactions with less alarm than 
at the beginning. It was particularly inter- 
esting thal none of the four patients whc 
received a second course of ALG had clini 
cally evident anaphylaxis. 
The  immunoIogic studies used to track 
the patient antibody responses against thc 
foreign protein were of some value in pre- 
dicting the possibility of an anaphylactic 
reaction-correlations that were similar to 
those in the classical studies of Longcope 
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and Rackman (21) almost 50 years ago. 7. STARZL, T. E., GROTH. C. G.. TERASAKI. P. I.. 
Precipitin titers, hemagglutinin titers, and PUTNAM, C. W.. BREITSCHNEIDER, L., MAR- 
CHIORO, T. L.: Heterologous antilymphocyte 
skin tests all had about the same degree of globulin, histocompatibility matching, and 
discrimination. However, neither a single human renal homotransplantation. Surg. 
- 
test nor any combination was infallible. Gynec. Obstet. In  press. 8. IWASAKI, Y., PORTER, K. A., AMEND, J. R., Moreover, it was possible to treat patients MARCHIORO, T. L., ZUHLKE, v.. STARZL. T. E.: 
for several months before an anaphylactic The preparation and testing of horse anti- 
* ,  
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reaction appeared despite clear evidence 
from the tests that such might eventually 
occur. 
The immunosuppressive qualities of 
ALG are believed, as judged by several a i -  
teria (14), to reside in the gamma G globu- 
lin. This fact, as well as the demonstration 
that the principal precipitin response to 
ALG is to the small quantities of non- 
essential alpha and beta globulins that it 
contains, raises the possibility of having a 
safer but equally potent ALG, since isola- 
tion of pure gamma G globulin is possible 
on a commercial basis. 
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